Biosimilars May Be Impacting Payers’ Medical Benefit Spend
Over the past decade, commercial per-member per-month (PMPM) drug spend under the medical benefit has almost doubled, according to Magellan Rx Management, a division of Magellan Health, Inc.
The company just released the 10th edition of its Medical Pharmacy Trend Report, which also found that 61% of payers were concerned with their medical benefit spend, up from 32% of payers who said this in the inaugural edition of the report.
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed DosesREAD MORE
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQviaREAD MORE